ReviewFrontiers in pharmacology2026
Biomedical applications and perspectives of two-dimensional porphyrin-based MOFs.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two-dimensional porphyrin-based metal-organic frameworks (2D Por-MOFs) have emerged as promising candidates in biomedical applications due to their ultrathin morphology, high surface area, tunable electronic properties, and excellent optical characteristics. This review systematically summarizes recent advances in their utilization for cancer therapy, antibacterial treatment, and biosensing. In oncology, 2D Por-MOFs serve as efficient photosensitizers for photodynamic therapy (PDT) by generating reactive oxygen species (ROS) to eradicate tumor cells, while also enabling synergistic therapeutic outcomes through integration with chemodynamic therapy (CDT), chemotherapy, immunotherapy, sonodynamic therapy (SDT), and novel mechanisms such as copper-dependent cell death. For antibacterial applications, these materials enhance ROS production via size engineering, single-atom modification, or nanozyme loading, effectively killing pathogens and promoting wound healing, as well as being incorporated into smart dressings to achieve combined hemostatic and antimicrobial functions. In biosensing, 2D Por-MOFs act as ideal platforms for photoelectrochemical signal transduction or fluorescent probes, facilitating the development of highly sensitive fiber-optic SPR, electrochemical, and fluorescence sensors capable of detecting disease biomarkers, pathogens, small-molecule metabolites, and ions with high sensitivity. Finally, the current challenges and future prospects for the clinical translation of 2D Por-MOFs are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.